全文获取类型
收费全文 | 94篇 |
免费 | 3篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 7篇 |
临床医学 | 2篇 |
内科学 | 17篇 |
皮肤病学 | 2篇 |
神经病学 | 41篇 |
特种医学 | 3篇 |
外科学 | 8篇 |
预防医学 | 8篇 |
眼科学 | 1篇 |
药学 | 7篇 |
出版年
2022年 | 1篇 |
2021年 | 2篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2016年 | 2篇 |
2015年 | 2篇 |
2014年 | 1篇 |
2013年 | 2篇 |
2012年 | 7篇 |
2011年 | 6篇 |
2010年 | 6篇 |
2009年 | 1篇 |
2008年 | 2篇 |
2007年 | 8篇 |
2006年 | 7篇 |
2005年 | 1篇 |
2004年 | 3篇 |
2003年 | 4篇 |
2002年 | 5篇 |
2001年 | 7篇 |
2000年 | 4篇 |
1999年 | 5篇 |
1998年 | 1篇 |
1996年 | 2篇 |
1993年 | 1篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 4篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1982年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有97条查询结果,搜索用时 15 毫秒
1.
Programmed electrical stimulation, also known as electrophysiologic studies (EPS), is a cardiologic technique used to help guide physicians in their management of selected patients with cardiac arrhythmias. Data are presented for 14 consecutive patients undergoing EPS seen in psychiatric consultation who had a diagnosis related to anxious mood. Successful management strategies, which evolved from work with these patients, included psychologic approaches (supportive psychotherapy and education) and psychopharmacologic agents (most commonly alprazolam). EPS and related physiologic aspects of anxiety and stress are briefly reviewed. 相似文献
2.
Zlot Amy I. Capizzi Jeff Bush Lea Menza Timothy W. 《Journal of immigrant and minority health / Center for Minority Public Health》2021,23(6):1348-1353
Journal of Immigrant and Minority Health - Over 8100 people living with HIV (PLWH) in Oregon are at risk of acquiring COVID-19, and communities of color are disproportionately impacted by both... 相似文献
3.
The personality associated with Parkinson’s disease 总被引:2,自引:0,他引:2
Menza M 《Current psychiatry reports》2000,2(5):421-426
Since at least 1913 reports have suggested there are personality traits and behaviors that are found premorbidly in those
who go on to develop Parkinson’s disease (PD). This premorbid personality consists of traits such as industriousness, punctuality,
inflexibility, cautiousness, and lack of novelty seeking and persists after the onset of the motor illness. The existence
of this personality remains controversial but is supported by case-based anecdotes, twin studies, and comparison of patients
with PD with medical control patients on standardized instruments. In addition a large number of epidemiologic studies show
that people who develop PD have low lifetime risks for cigarette smoking, coffee drinking, and alcohol consumption, again
suggesting that there is a behavior pattern that predates PD. Despite the retrospective nature of much of these data, the
use of nonstandardized instruments, and diffuse concepts of personality, the great majority of studies show striking similarity
in identifying these traits. An integrating hypothesis, involving damage to dopaminergic systems, known to predate the onset
of the motor illness, is discussed. 相似文献
4.
Myocardial dysfunction in patients with aortic stenosis and hypertensive heart disease assessed by MR tissue phase mapping 下载免费PDF全文
5.
Casiglia E Pizziol A Tikhonoff V Mazza A Di Menza G Palatini P Gambino A Cerutti A Pessina AC Casarotto D 《American heart journal》2000,140(6):941-944
BACKGROUND: This study was aimed at investigating whether a circadian rhythm of peripheral resistance exists in patients with orthotopic cardiac transplantation (OCT) and whether it parallels that of blood pressure (BP). METHODS: BP and leg flow and resistance (plethysmography) were monitored for 24 hours in 13 denervated OCT recipients and 13 control patients with native heart, matched for casual blood pressure. RESULTS: On the basis of BP trend, control patients showed a BP reduction during sleep, whereas OCT recipients did not. Leg resistance was significantly lower and leg flow significantly higher during sleep than during waking in all patients, and the extent of the nocturnal decrease was similar in the two categories. CONCLUSIONS: The decrease in leg resistance in patients confined to bed for 24 hours is caused by peripheral mechanisms and does not depend on the autonomic control of the heart. The nocturnal decline in BP depends, on the contrary, on cardiac control and is lost in patients with denervated heart. 相似文献
6.
BACKGROUND: Most patients with depression continue to have symptoms after treatment. It is well documented that these "residual" symptoms are common and are associated with increases in suboptimal long-term outcomes such as relapse and disability. While it is clear that residual symptoms, as a group, contribute to poor outcomes, individual residual symptoms have received relatively little attention. To some extent, this lack of attention reflects an uncertainty in the field about the relationship of the syndrome of depression to the symptoms by which the syndrome is defined. METHOD: Recognizing that for clinicians and patients symptom relief is the goal of treatment, this article reviews the evidence that a symptomatic approach to individual residual symptoms is both feasible and useful. Evidence was gathered through a MEDLINE review of articles published in English from 1966 to 2002. Multiple keywords relating to symptoms, depression, and treatment were used. RESULTS: Many of the agents that psychiatrists use for augmentation of depression treatment, such as psychostimulants and alerting agents, atypical antipsychotics and mood stabilizers, and buspirone and benzodiazepines, have specific symptomatic effects, which raises the question of whether we are augmenting the core antidepressant effect or providing symptomatic relief. Fatigue, anxiety, sexual dysfunction, and sleep disturbances are all symptoms that are commonly leftover after treatment of depression. Some data indicate that treatment of these residual symptoms is efficacious and may affect the long-term outcome of depression. DISCUSSION: This discussion of the treatment of residual depressive symptoms raises a variety of research questions that should be addressed. Also implicit in this discussion are theoretical questions on the relationship between symptoms and syndrome. 相似文献
7.
DeBattista C Doghramji K Menza MA Rosenthal MH Fieve RR;Modafinil in Depression Study Group 《The Journal of clinical psychiatry》2003,64(9):1057-1064
BACKGROUND: Fatigue and sleepiness are primary symptoms of depression that may not resolve with antidepressant therapy. Modafinil is a novel agent that has been shown to improve wakefulness and lessen fatigue in a variety of conditions. In this study, we examined the utility of modafinil as an adjunct therapy to treat fatigue and sleepiness in patients with major depression who are partial responders to antidepressants. METHOD: Patients with partial response to anti-depressant therapy given for at least a 6-week period for a current major depressive episode (DSM-IV criteria) were enrolled in this 6-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Patients received once-daily doses (100-400 mg) of modafinil or matching placebo as adjunct treatment to ongoing antidepressant therapy. The effects of modafinil were evaluated using the Hamilton Rating Scale for Depression (HAM-D), the Fatigue Severity Scale (FSS), the Epworth Sleepiness Scale (ESS), the Clinical Global Impression of Change (CGI-C), and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Adverse events were monitored throughout the study. RESULTS: One hundred thirty-six patients were randomized to treatment, with 118 patients (87%) completing the study. Most patients (82%) were fatigued, and one half of patients (51%) were sleepy. Modafinil rapidly improved fatigue and daytime wakefulness, with significantly greater mean improvements from baseline than placebo in fatigue (FSS) scores at week 2 (p < .05) and sleepiness (ESS) scores at week 1 (p < .01); the differences between modafinil and placebo at week 6 were not statistically significant. Assessment of the augmentation effects of modafinil (HAM-D, CGI-C, and SF-36) did not significantly distinguish modafinil from placebo. Modafinil was well tolerated in combination with a variety of antidepressants. CONCLUSION: Modafinil may be a useful adjunct therapy for the short-term management of residual fatigue and sleepiness in patients who are partial responders to antidepressant therapy. 相似文献
8.
Pancreatic encephalopathy 总被引:15,自引:0,他引:15
9.
Decreased extrapyramidal symptoms with intravenous haloperidol 总被引:2,自引:0,他引:2
In a preliminary, prospective study, the intensity of extrapyramidal symptoms was rated in four patients receiving intravenous haloperidol and six patients receiving oral haloperidol. The raters were blind to the route of administration. In this pilot study, the first systematic evaluation of intravenous haloperidol and extrapyramidal symptoms, the patients receiving intravenous haloperidol experienced significantly (p less than .01) less intense extrapyramidal symptoms than did the patients receiving oral haloperidol. The literature on intravenous haloperidol is briefly reviewed, and possible explanations of the lower intensity of extrapyramidal symptoms with intravenous haloperidol in the patients studied are discussed. 相似文献
10.
Renato De Stefano Elena Frati Fernando Nargi Caterina Baldi Luana Menza Mohammed Hammoud Mauro Galeazzi 《Clinical rheumatology》2010,29(5):517-524
To compare the efficacy and safety of leflunomide (LEF)-anti-TNF-alpha combination therapy to methotrexate (MTX)-anti-TNF-alpha
combination therapy in a group of patients with active rheumatoid arthritis (RA). We have recruited 120 patients with RA with
a high disease activity despite being treated with MTX (15 mg/week) or LEF (20 mg/die) for 3 months, without side effects.
In each of these patients, therapy with either MTX or LEF was continued and randomly combined with an anti-TNF-alpha drug:
etanercept, infliximab, or adalimumab. Patients were assessed at study entry and at 4, 12, and at 24 weeks. The efficacy endpoints
included variations in the DAS28-ESR and the ACR20, ACR50, and ACR70 responses. At each visit, any side-effect was recorded.
There were no statistically significant differences in the DAS28 variations and in the ACR responses between the two groups
or among the six subgroups. The number of discontinuation due to the appearance of serious side effects was higher, but not
statistically significant, in the LEF-anti-TNF-alpha group than in the MTX-anti-TNF-alpha group. Other adverse events that
did not necessitate the discontinuation of therapy occurred much more frequently in patients treated with MTX than in those
treated with LEF. Anti-TNF-alpha drugs can be used in combination not only with MTX, but also with LEF, with the same probability
of achieving significant clinical improvement in RA patients and without a significantly greater risk of serious adverse events.
In contrast, it seems that combination therapy with LEF-anti-TNF-alpha is more readily tolerated than combination therapy
with MTX-anti-TNF-alpha. 相似文献